Pseudoxanthoma Elasticum (PXE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Pseudoxanthoma elasticum (PXE) arises from mutations in the ABCC6 gene and is a hereditary metabolic disorder. It is characterized by the gradual calcification and breakage of elastic fibers in the skin, retina, and arterial walls. Typically, this condition manifests during adolescence or young adulthood, but it can emerge at any stage of life. The initial clinical indication is nearly always the appearance of small yellow papules on the back of the neck, sides of the neck, and in areas where the skin flexes. In some individuals, PXE may be confined to a single organ (skin, eyes, or blood vessels); in others, it can affect two or all three of these organs. Although cardiac issues like angina pectoris and myocardial infarction are relatively uncommon, they require thorough examination when present. Most PXE cases stem from two pathogenic variations in the ABCC6 gene, located at 16p13.11. In rare instances, patients displaying clinical features resembling PXE may possess pathogenic variations in the ENPP1 gene at 6q23.2, typically associated with generalized arterial calcification of infancy (GACI). There is no specific cure for PXE, and treatment primarily addresses symptoms. This can involve direct injections of vascular endothelial growth factor inhibitors into the eyes to manage choroidal neovascularization, adopting lifestyle changes, implementing lipid-lowering measures and dietary adjustments to reduce vascular risk factors, performing vascular surgery in cases of severe arteriosclerosis, and opting for plastic surgery to address excess skin folds. PXE is a progressive, lifelong condition with significant potential for debilitation, but most patients can expect a normal lifespan.
• According to the literature review conducted by Thelansis, the prevalence of PXE, estimated to be 1 in 50,000, would imply that there are ~8,000–10,000 PXE patients in the United States. With the global prevalence, as many as 160,000 to 200,000 patients could be affected by PXE worldwide.

Thelansis’s “Pseudoxanthoma Elasticum (PXE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pseudoxanthoma Elasticum (PXE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Pseudoxanthoma Elasticum (PXE) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Pseudoxanthoma Elasticum (PXE) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Pseudoxanthoma Elasticum (PXE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Pseudoxanthoma Elasticum (PXE), Pseudoxanthoma Elasticum (PXE) market outlook, Pseudoxanthoma Elasticum (PXE) competitive landscape, Pseudoxanthoma Elasticum (PXE) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)